Home › Diffuse Intrinsic Pontine Glioma › Pennsylvania
Diffuse Intrinsic Pontine Glioma clinical trials in Pennsylvania
13 studies for Diffuse Intrinsic Pontine Glioma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Nov 4, 2026 · NCT04837547Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 1 to 26 · All sexes · Updated Oct 28, 2026 · NCT07680439ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Children's Hospital of Philidelphia, Philidelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Oct 23, 2026 · NCT06838676CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944Targeted Pediatric High-Grade Glioma Therapy
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Combination Therapy for the Treatment of Diffuse Midline Gliomas
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 2 to 39 · All sexes · Updated Jun 26, 2026 · NCT05009992Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.